Format

Send to

Choose Destination
Vaccine. 2006 May 15;24(20):4312-20. Epub 2006 Mar 20.

Evaluation of a novel Vi conjugate vaccine in a murine model of salmonellosis.

Author information

1
The Wellcome Trust Genome Campus, The Wellcome Trust Sanger Institute, Hinxton, Cambridge, CB10 1SA, UK. cbh@sanger.ac.uk

Abstract

Immunisation of BALB/c mice with a vaccine containing Vi polysaccharide conjugated to the Klebsiella pneumoniae outer membrane 40 kDa protein (rP40), in combination with Escherichia coli heat-labile toxin adjuvant (LT), elicited anti-Vi IgG antibodies after administration using different routes. Testing of the immune serum in opsonisation assays demonstrated the specific enhancement of Vi-positive bacterial uptake by cultured murine bone marrow derived macrophages. Intra-peritoneal challenge of mice immunised with the Vi-based vaccine elicited a degree of protection against virulent Vi+ Salmonella enterica serovar typhimurium (S. typhimurium). In contrast, Vi vaccination did not confer protection against oral challenge with virulent Vi-positive S. typhimurium or S. dublin.

PMID:
16600446
DOI:
10.1016/j.vaccine.2006.03.002
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center